Inventor · disambiguated record
Jie Fei Cheng
Also filed as: CHENG JIE · CHENG JIE F · CHENG JIE FEI
16 granted patents·8 pending applications·63 citations·filing 1994–2025
90Inventor score
Files withCHUGAI PHARMACEUTICAL CO LTD13TRIASTEK INC3ARRHENIUS THOMAS2Bayer Pharma AG2Beijing Changping Laboratory1
Top patents by PatentIndex Score
24 records- 0186US7449482B2Piperidine compounds useful as malonyl-CoA decarboxylase inhibitorsCHUGAI PHARMACEUTICAL CO LTD·Filed 2004·Granted Nov 11, 2008·25 cites·5 claims
- 0275US2025262164A1Oral drug dosage forms having a desired pk profile and methods of designing and producing thereofTRIASTEK INC·Filed 2025·Application pending·0 cites
- 0374US7026491B2Coumarin derivatives useful as TNFα inhibitorsCHUGAI PHARMACEUTICAL CO LTD·Filed 2001·Granted Apr 11, 2006·6 cites·3 claims
- 0474US5514708ACytotoxic metabolites from Myriapora truncataPHARMAMAR SA·Filed 1994·Granted May 7, 1996·14 cites·3 claims
- 0572US6730796B2Process for preparation of N-substituted 2-sulfanylimidazolesCHUGAI PHARMACEUTICAL CO LTD·Filed 2001·Granted May 4, 2004·10 cites·9 claims
- 0669US7385063B2Method for preparing imidazole derivativesCHUGAI PHARMACEUTICAL CO LTD·Filed 2002·Granted Jun 10, 2008·5 cites·12 claims
- 0766US7696365B2Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitorsCHUGAI PHARMACEUTICAL CO LTD·Filed 2004·Granted Apr 13, 2010·3 cites·5 claims
- 0862US2021196638A1Oral drug dosage forms having a desired pk profile and methods of designing and producing thereofTRIASTEK INC·Filed 2021·Application pending·0 cites
- 0958US7709664B2Coumarin derivatives useful as TNFα inhibitorsCHUGAI PHARMACEUTICAL CO LTD·Filed 2005·Granted May 4, 2010·0 cites·2 claims
- 1057US2024041779A1Delayed sustained-release oral drug dosage forms of a janus kinase (jak) inhibitor and methods of useTRIASTEK INC·Filed 2021·Application pending·0 cites
- 1155US8119819B2Malonyl-CoA decarboxylase inhibitors useful as metabolic modulatorsARRHENIUS THOMAS·Filed 2009·Granted Feb 21, 2012·0 cites·4 claims
- 1255US8080665B2Piperidine compounds useful as malonyl-CoA decarboxylase inhibitorsCHENG JIE FEI·Filed 2008·Granted Dec 20, 2011·0 cites·3 claims
- 1354US2008070869A1Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic ModulatorsCHUGAI PHARMACEUTICAL CO LTD·Filed 2007·Application pending·0 cites
- 1453US7994318B2Coumarin derivatives useful as TNFα inhibitorsCHUGAI PHARMACEUTICAL CO LTD·Filed 2010·Granted Aug 9, 2011·0 cites·3 claims
- 1553US7872142B2Coumarin derivatives useful as TNFα inhibitorsCHUGAI PHARMACEUTICAL CO LTD·Filed 2010·Granted Jan 18, 2011·0 cites·2 claims
- 1652US7786145B2Cyanoguanidine-based azole compounds useful as malonyl-CoA decarboxylase inhibitorsCHUGAI PHARMACEUTICAL CO LTD·Filed 2004·Granted Aug 31, 2010·0 cites·3 claims
- 1751US2025275958A1Gpcr regulator and use thereofBeijing Changping Laboratory·Filed 2023·Application pending·0 cites
- 1850US7709510B2Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulatorsCHUGAI PHARMACEUTICAL CO LTD·Filed 2002·Granted May 4, 2010·0 cites·8 claims
- 1947US7279477B2Malonyl-CoA decarboxylase inhibitors useful as metabolic modulatorsCHUGAI PHARMACEUTICAL CO LTD·Filed 2002·Granted Oct 9, 2007·0 cites·14 claims
- 2043US2019038632A1Copanlisib biomarkersBayer Pharma AG·Filed 2017·Application pending·0 cites
- 2140US8110686B2Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulatorsARRHENIUS THOMAS·Filed 2010·Granted Feb 7, 2012·0 cites·4 claims
- 2240US7723366B2Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseasesCHUGAI PHARMACEUTICAL CO LTD·Filed 2002·Granted May 25, 2010·0 cites·2 claims
- 2338US2019382839A1Copanlisib biomarkersBayer Pharma AG·Filed 2017·Application pending·0 cites
- 2438US2005113514A14-N-acyl-delta 5-2-oxopiperazines, a process for its preparation and combinatorial libraries thereofFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jie Fei Cheng files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →